Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499642 | 1.00 | EGLN1 (0.48) | EGLN1CDK2PYGLMETTL3NOS2 | |
| SCHEMBL3498817 | 0.92 | EGLN1 (0.52) | EGLN1METTL3 | |
| SCHEMBL3498816 | 0.92 | EGLN1 (0.52) | EGLN1METTL3 | |
| SCHEMBL3497393 | 0.87 | GPR34 (0.55) | EGLN1CDK2PYGL | |
| SCHEMBL3497391 | 0.87 | GPR34 (0.55) | EGLN1CDK2PYGL | |
| SCHEMBL3499523 | 0.85 | EGLN1 (0.52) | EGLN1CDK2NOS2 | |
| SCHEMBL3499520 | 0.85 | EGLN1 (0.52) | EGLN1CDK2NOS2 | |
| SCHEMBL3501142 | 0.80 | PTPN1 (0.50) | EGLN1CDK2 | |
| SCHEMBL3501139 | 0.80 | PTPN1 (0.50) | EGLN1CDK2 | |
| SCHEMBL3501151 | 0.80 | GPR34 (0.47) | EGLN1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | EGLN1 1231/4885CDK2 2075/4885PYGL 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.